Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial
is studying how well AZD2171 works in treating patients with locally advanced or metastatic
liver cancer.